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ABSTRACT: The objective of the study was to evaluate the therapeutic efficacy
of nicotine nasal solution (NNS) for smoking cessation from the stopping day up
to 3 months. We also followed the participants for 2 yrs after ceasing smoking to
assess what happens after stopping using NNS.
In a placebo-controlled, double-blind, 2 yr prospective study, 157 smokers were
given either NNS, one dose containing 1 mg of nicotine per 100 µL (n=79), or place-
bo (n=78). Treatment was continued for up to 1 yr.
One day after quitting smoking, the average number of daily doses was 11 in
the group assigned NNS and 14 in the group assigned the placebo, and after 6
weeks, 14 and 6 doses, respectively, among abstinent participants still using spray.
After 3 months, 65% of the abstainers in the nicotine group were still using the
NNS. The abstinence rates were 51, 39 and 29% after 6 weeks, 3 and 6 months,
respectively, as compared to 24, 19 and 18% in the placebo group (p=0.0003;
p=0.003; p=0.050). The proportion abstinent at the 1 yr (25 vs 17%) and 2 yr fol-
low-ups (19 vs 14%) was higher among those assigned to the nicotine than to the
placebo group, but not significantly so for the numbers used in the study.
In conclusion, the use of nicotine nasal spray significantly increased the absti-
nence rate during the first 6 months following the quitting day.
Eur Respir J 1997; 10: 1585–1590.
*Reykjavik Health Care Center, Iceland.
+National University Hospital, Reykjavik,
Iceland. **Pharmacia & Upjohn Consumer
Health Care, Columbus, Ohio, USA. †Phar-
macia & Upjohn Consumer Health Care,
Helsingborg, Sweden.
Correspondence: T. Blöndal
Reykjavik Health Care Center
Baronstigur 47
101 Reykjavik
Iceland
Keywords: Nicotine
nicotine delivery system
nicotine nasal spray
smoking cessation
Received: August 15 1996
Accepted after revision April 18 1997
This study was supported by the Icelandic
Ministry of Health and Social Security
(grant), and Pharmacia & Upjohn (equip-
ment, drugs).
The use of nicotine combined with group support dur-
ing the initial period after stopping smoking, has been
shown to be of value in numerous investigations. Nico-
tine polacrilex gum and nicotine transdermal patches [1,
2] are well established as aids to smoking cessation.
Other nicotine delivery systems include nasal spray [3–
5], which has now been approved for use in 11 coun-
tries, and a nicotine inhaler [6].
The aim of this study was to investigate the effect of
a nicotine nasal spray (NNS) in the withdrawal phase
of smoking cessation. Nicotine absorption is slow from
nicotine polacrilex gum and particularly so from the
transdermal patch. The serum nicotine levels attained
are far below pretreatment smoking levels. Serum nico-
tine levels in gum users are seldom more than one third
those of smoking levels [1], while the nicotine from
nasal sprays is absorbed sufficiently rapidly to produce
subjective effects similar to those from smoking and pro-
duce blood levels of ~40% of the smoking range [3, 7].
We attempted to investigate the effect of nicotine
nasal spray treatment for up to 3 months and to assess
the abstinence rates up to 1 yr after stopping the use of
nicotine spray (2 yrs after quitting smoking).
Methods
Subjects and randomization
Recruitment for the study was done by newspaper ad-
vertisement in the second half of 1989. To be eligible,
subjects had to be 21–68 yrs old and had to smoke at
least 1 cigarette·day-1. Subjects had to be motivated to
stop smoking and be willing to adhere to the trial pro-
tocol. The trial was conducted in accordance with the
Helsinki declaration, as amended in Venice 1983, and
was approved by the Ethics Committee of the University
Hospital in Reykjavik. The criteria for exclusion were
a history of recent myocardial infarction, severe aller-
gy, current abuse of alcohol or other drugs, and preg-
nancy/breast-feeding. Use of psychoactive medications
was not an exclusion criterion and neither was former
nicotine replacement therapy (NRT). Those interested
in participating were scheduled for an appointment and
underwent initial screening by telephone. A total of 178
attended the screening interview in the clinic. Of those
178 initially found eligible, 158 attended the first group
session, entered the trial and were randomized.
The study medication (nicotine or placebo) was dis-
pensed by the University Hospital pharmacy. The sub-
jects were assigned to either nicotine or placebo treatment
according to a computer-generated randomization code.
Seventy nine subjects were assigned the active treatment
and 78 the placebo spray. One subject was excluded 1
week after randomization because of noncompliance
with protocol requirements. During the first 6 weeks,
supportive treatment was given during group sessions,
with the 157 participants divided into seven hetero-
geneous groups, the participants in each group receiv-
ing either the nicotine spray or a placebo. Subjects and
therapists were blind to treatment assignment.
Study population
The baseline characteristics of the study population
are shown in table 1. The values for all variables were
similar in both groups. Forty men and 39 women receiv-
ed nicotine treatment and 30 men and 48 women receiv-
ed the placebo.
Nasal nicotine spray (NNS)
The NNS device (supplied by Pharmacia & Upjohn
Consumer Health Care, Helsingborg, Sweden) consisted
of a pocket-sized, multidose bottle with a pump mecha-
nism fitted to a nozzle for insertion into the nostril. The
active spray delivered 0.5 mg of nicotine per 50 µL
squirt. One dose consisted of two squirts, one into each
nostril (a total of 1 mg of nicotine). The placebo spray
contained black pepper oleo resin (piperine) to mimic
the sensory effect of nicotine. Spray use was on an ad
libitum basis, allowing up to a maximum of 5 doses·h-1
(5 mg of nicotine) and 40 doses·day-1 (40 mg of nico-
tine). A leaflet with an instructive picture was provid-
ed and emphasis was placed on teaching the correct
technique for using the spray, which was repeatedly dis-
cussed at group sessions. Subjects were advised to use
the spray whenever they felt an urge to smoke. The rec-
ommended duration of use was 3 months, but subjects
who felt a need to continue beyond this time were stron-
gly encouraged to do so. No nasal spray was dispensed
after the 1 yr follow-up. Furthermore, no formal dose
reduction scheme to wean subjects off the spray was
imposed.
Group treatment and clinic visits
Supportive treatment consisted of six group sessions
over 43 days, each lasting 1 h. A first preliminary meet-
ing was held mainly to inform the subjects about nasal
spray usage. Those who did not attend this meeting were
not randomized. The day after this first group session
was defined as the "quitting day" or "day zero". The
next session took place one day after day zero and was
followed by five group sessions, which were held 6, 8,
15, 22 and 43 days after day zero. Attendance at the
six meetings was as follows: 98% (day 1), 99% (day
6), 85% (day 8), 76% (day 15), 68% (day 22) and 59%
at the last group meeting, after 43 days. At these meet-
ings, the need for a change in attitude towards smoking
was emphasized. The supportive treatment was group-
orientated and did not follow any formal behavioural
scheme. At the sessions a comfortable atmosphere was
created in which the participants could support each
other and discuss various methods available to remain
free of smoking and how to cope with difficult situa-
tions. All the participants received an instruction book-
let on how to stop smoking. Individual follow-ups
were carried out 3, 6, 12 and 24 months after the start
of treatment. At these times, all of the subjects were
contacted by telephone and those reporting abstinence
were asked to attend a "validation appointment". Cur-
rent smokers provided details by telephone only.
Measures
During all visits up to 12 months, each subject was
requested to fill in questionnaires on the number of cig-
arettes smoked between visits, the use of any nicotine
treatment other than that prescribed and any adverse
reactions, i.e. nose irritation, throat irritation, cough,
sneezing, watery eyes, rhinorrhoea, palpitations, nausea,
sweating, headache, any calming effect and dizziness.
Each adverse reaction was graded as "mild", "moderate"
or "severe" and the corresponding numeric score of 1,
2 and 3 was registered. Adding the score registered at
each visit made up the total score for each adverse reac-
tion. Any craving for cigarettes, along with reports of
one or more of 10 other symptoms, (i.e. irritation, bore-
dom, tiredness, dizziness, headache, increased appetite,
difficulties in concentrating, sleep disturbances, lack of
energy) and an open question about any other symp-
tom, was also recorded at baseline and up to the 6 month
follow-up. Each participant responded to the Fagerström
Tolerance Questionnaire (FTQ), with an assessment of
nicotine dependence, and was rated from zero to a max-
imum of 11 [8]. A visual analogue scale, with a rating
from zero to 10, was used by the subjects to assess the
usefulness of nasal spray treatment.
Verification of nonsmoking status
At the baseline assessment, subjects provided a smo-
king history. On the same occasion (and at all later
visits) carbon monoxide (CO) was measured (using an
EC50 monitor, Bedfont, Technical Instruments, Sitting-
bourne, UK). Subjects were instructed to inhale deeply
and to hold their breath for 10–15 s before expiring
with full force through the inflow valve of the monitor.
Levels of 9 parts per million (ppm) or lower were con-
sidered to indicate a nonsmoking status [9]. Subjects
were weighed (with indoor clothes but without shoes)
at assessment, after 9 days, 6 weeks, and 3, 6, 12 and
24 months. The amount of nasal spray used was record-
ed in a daily diary and also at group sessions and indivi-
dual follow-ups, along with any smoking that occurred
between visits.
Determination of abstinence
The 157 subjects formed the base both of abstinence
rates and the survival table analysis. At the follow-ups
on days 1, 6, 8, 15, 22, 43, 91, 182, 365 and 730, the
criterion for recording the "lapse free abstinence" (LFAT)
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Table 1.  –  Baseline characteristics of the study popu-
lation
Characteristics NNS group Placebo group
at entry
Sex  M/F 40/39 30/48
Age  yrs 42 (22–67) 42 (21–67)
Amount smoked g·day-1 26 (4–50) 24 (6–45)
Salival cotinine ng·mL-1 410 430
Baseline CO  ppm 29 (3–80) 29 (2–57)
FTQ 7.1 (3–10) 7.3 (4–10)
Duration of smoking 2.7 (1–5) 2.7 (1–5)
10 yr periods
Values are presented as absolute value, or as mean  with range
in parenthesis. NNS: nicotine nasal spray; M: male; F: female;
FTQ: Fagerström Tolerance Questionnaire, an assessment of
nicotine dependence, maximum 11.
was continuous abstinence from day zero. The LFAT
ended permanently (terminal event) if a subject started
smoking on a daily, or occasional basis, or if a subject
admitted using another nicotine replacement therapy,
including nicotine gum and patch, during the study peri-
od. At the follow-up visits, nonsmoking claims were
confirmed by a CO measurement of <10 ppm. One sub-
ject lost to follow-up was assumed to be a smoker.
Subjects who failed to keep their appointments usually
had resumed smoking and were contacted by telephone
regularly at the follow-up times throughout the study.
For the life table analysis, the day when LFAT stopped
was registered for each subject.
Determination of cotinine in saliva
Cotinine is a major metabolite of nicotine and is a
useful marker. A sample of at least 3 mL of unstimu-
lated saliva was collected in a plastic cup at each visit,
usually in the afternoon, sealed and frozen at -20°C,
within 1 h. The saliva samples were analysed at the
Pharmacia & Upjohn laboratory by gas chromatography
[10, 11]. Throughout the study the measures of cotinine
were not used to validate claims of abstinence, as this
would have meant applying a more stringent criterion
to the placebo than to the active group.
Statistical analysis
The study was designed to detect at least a 20% sig-
nificant difference between active treatment and place-
bo at 3 months, with observation of abstinence rates
for up to 1 yr. The observation time was later extend-
ed to include a 2 yr follow-up as well, although this
was not originally planned. It was projected, from pre-
vious trials using nicotine replacement procedures, that
the placebo would yield a success rate of about 15%,
while the new treatment was expected to yield a rate
of 35% (at 3 months). The minimum number of sub-
jects was set to 2×56 to achieve a Type II error of 20%
if the Type I error was 5%. The difference between
active and placebo groups in abstinence rates at the dif-
ferent follow-up times was assessed by the chi-square
test. For calculation of the proportion remaining absti-
nent over time, a life table procedure, which compared
the survival of the subgroups, was performed [12]. For
comparing variation among the means of more than
two groups, multiple analysis of variance was used. In
view of all the evidence suggesting the relative effec-
tiveness of nicotine replacement, one-sided probability
tests were used when comparing abstinence rates at the
follow-up visits. In all other comparisons, two-sided
probability tests were used. A p-value of less than 0.05
was considered significant.
Results
Abstinence
After one day, there was a significant difference in
abstinence rates between the study groups. This diffe-
rence was maintained at the follow-up visits up to 6
months after the quitting day, but not at the 1 and 2 yr
follow-up visits (table 2). The rates of total abstinence
for 6 weeks, 3 months and 6 months were 51, 39 and
29% in the nicotine spray group and 24, 19 and 18%
in the placebo spray group respectively (p=0.0003; p=
0.003; p=0.050). At the 2 yr follow-up, 19% of the par-
ticipants receiving active treatment were found to have
been completely abstinent throughout the 2 yr period,
compared to 14% of the placebo participants.
The survival analysis, with the proportion abstinent
as the survival variable, is shown in figure 1. Placebo
subjects were less likely to maintain abstinence during
the group session period than those on active therapy.
The median survival at the 2 yr follow-up visit was 49
days among participants assigned nicotine vs 10 days
for those assigned the placebo. Comparison of the sur-
vival experience in the two treatment groups, using the
Wilcoxon (Gehan) statistic, yielded an average score of
22.2 for active and -22.5 for placebo groups, with a sig-
nificance level of p=0.002.
Background factors
Age, initial level of tobacco consumption, cotinine
levels, FTQ and initial carbon monoxide value were not
related to type of therapy or to relapse in smoking, both
after 43 days and after 2 yrs.
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Table 2.  –  Percentage of participants abstinent* at fol-
low-ups
Follow-up NNS Placebo p-value Estimated
time (n=79) (n=78) relative risk
% % 95% CL
1 day 94 (74) 82 (64) 0.013 3.24 1.11–9.48
6 days 73 (58) 58 (45) 0.020 2.03 1.03–3.96
8 days 71 (56) 53 (41) 0.009 2.20 1.14–4.24
15 days 59 (47) 40 (31) 0.007 2.23 1.18–4.22
22 days 59 (47) 26 (23) <0.0001 3.51 1.81–6.81
43 days 51 (40) 24 (19) 0.0003 3.18 1.61–6.28
3 months 39 (31) 19 (15) 0.003 2.71 1.32–5.58
6 months 29 (23) 18 (14) 0.050 1.88 0.88–3.99
1 yr 25 (20) 17 (13) 0.092 1.69 0.78–3.71
2 yrs 19 (15) 14 (11) 0.205 1.42 0.61–3.34
*Continuous prevalence rates after day zero. No smoking and
only prescribed nicotine permitted. Expired CO <10 parts per
million (ppm) at follow-ups. Values are presented as percen-
tage, with absolute number in parenthesis. NNS: nicotine
nasal spray; 95% CL: 95% confidence limit. 
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Fig. 1.  –  Proportion of abstinent subjects by day for 2 yrs. Those
receiving the placebo (- - - - -) relapsed much sooner than those using
the nicotine nasal spray (——).
Use of nasal spray
All participants used the spray they were assigned
at least once. The proportion of abstinent subjects still
using the spray and the average number of daily doses
at each follow-up is shown in table 3. Among subjects
assigned nicotine, the number of doses used remained
high throughout the first year, after which no more NNS
was dispensed. The percentage of total (n=79) NNS
spray users was 25, 19 and 11% at 3, 6 and 12 months,
respectively. The percentage of NNS spray users among
the abstainers at each follow-up visit was 65, 65 and
45% respectively. For daily NNS users (≥1 dose·day-1),
mean salival levels of cotinine during the first 3 weeks
were one quarter of baseline smoking levels. After 6
weeks and 3 months the substitution level was 32 and
46%, respectively (fig. 2). For the subjects remaining
on the spray for longer time periods, levels of substi-
tution were much higher (fig. 2). At 12 months, nine
out of 20 abstainers in the active group (45%) were still
using the NNS, averaging 24 doses·day-1. Retrospec-
tively, it was seen that these nine subjects had used
more doses than the average throughout the study (at 7
days=17 doses, at 23 days=20 doses, at 3 months=23
doses and at 6 months=26 doses). During the second
year of the study, when they no longer had access to
NNS, four out of these nine resumed smoking. The pro-
portion of abstinent placebo spray users dropped rapid-
ly after the first 8 days, and at the 3 month follow-up
visits no one in the placebo group was using the spray.
The helpfulness of the spray, compared to a cigarette
(linear scale 0 to 10), was rated significantly higher by
subjects who were assigned to using the active NNS
spray than by subjects assigned to the placebo (table 4).
Tobacco withdrawal symptoms
Among all abstinent participants, the total score for
withdrawal symptoms (a possible maximum of 44) reached
a peak 2 days after quitting, as compared to the base-
line score, and decreased between group meetings until
day 22, when it had reached a plateau that remained
essentially unchanged throughout the first year. Abstinent
subjects on the active spray experienced fewer with-
drawal symptoms at the first two group meetings after
quitting (fig. 3) than did the participants on the place-
bo (t-test, p=0.01, 0.005).
Adverse effects
By adding the individual scores for the different ad-
verse effects, a total score was obtained with a possible
maximum of 36. Subjects on the active spray experi-
enced more side-effects on the first day (p<0.001) after
stopping smoking than the participants on the placebo
(fig. 4).
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Table 3.  –  Proportion of abstinent nasal spray users
in the two treatment groups and mean number of doses
used per day
NNS (n=79)              Placebo (n=78)
Follow-up Abst Using Dose Abst Using Dose
time spray spray
days n % n % 
1 74 100 11±8 63 98 14±10
6 58 97 13±8 45 98 17±9
8 56 91 14±8 41 93 14±9
15 47 89 14±9 31 74 15±8
22 46 83 14±10 23 57 14±9
43 40 73 14±13 19 42 6±5
91 31 65 20±17 15 0 -
182 23 65 21±15 14 0 -
365 20 45 24±15 13 0 -
Abst: abstainers; NNS: nicotine nasal spray. Dose: doses used,
expressed as mean±SD doses·day-1.
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Fig. 2.  –  Level of substitution (of pretreatment salival cotinine 410
ng·mL-1) in daily nicotine nasal spray (NNS) users at each follow-up
(—●—) and in nine subjects still using NNS at the 12 month follow-
up (- -■- -).
Table 4.  –  How helpful was the nasal solution com-
pared to a cigarette?
NNS                Placebo        p-value
Follow-up n Mean n Mean (t-test)
time score* score*
1 day 73 5.9 62 3.9 0.001
6 days 53 6.1 41 3.9 0.001
8 days 44 6.5 32 4.6 0.005
15 days 36 7.2 19 4.9 0.005
22 days 35 6.5 13 5.5 0.277
43 days 24 7.6 7 4.2 0.002
3 months 19 8.4 2 3.7 0.003
6 months 15 9.1 0 -
12 months 9 9.3 0 -
*Score calculated using a linear scale of 0–10. NNS: nicotine
nasal spray; n: number of subjects.
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Fig. 3.  –  Withdrawal symptoms during the first 23 days after quit-
ting. At the first two group sessions, the score was lower among sub-
jects assigned to active NNS spray, but thereafter no significant
difference in withdrawal score was noted between the groups.     :
nicotine nasal spray group;     : placebo group.
Among the subjects using NNS for a period of 6
weeks, adverse effects in general most often seemed to
diminish with duration of use (table 5). After 1 day,
23% of the subjects rated the adverse effects as "no
problem" and after 43 days of use the corresponding
figure was 48%. After 1 day of use, 56% of the sub-
jects labelled the adverse effects as "not serious" and
after 43 days the figure was 48%; 18% of the partici-
pants recorded the adverse effects as "uncomfortable"
after 1 day of use and only 4% after 43 days of use.
Likewise, 3% of the subjects found the adverse effects
to be "unacceptable" after 1 day whereas none of the
participants rated the adverse effects as unacceptable
after 43 days.
Among the placebo spray users, sweating was sig-
nificantly more frequent at all five group meetings dur-
ing the first 22 days of the study, and was the only
side-effect more common in the placebo group.
Weight gain
Analysis of weight gain was confined to subjects
abstaining from smoking at each follow-up. The mean
weight gain in the subjects enjoying lapse-free absti-
nence at 3 months, 6 months, and 1 and 2 yrs after stop-
ping smoking was 3.6 kg (4.7%), 5.3 kg (6.9%), 6.6 kg
(8.3%) and 5.7 kg (7.4%) respectively. There was no
difference in weight gain according to treatment.
Discussion
To our knowledge, this study is the fourth [3–5] to
assess the efficacy of NNS in smoking cessation. What
is interesting about these four studies is that the results
are similar despite several differences in criteria (table
4). In the present study and the study of SCHNEIDER et al.
[5], continuous abstinence from day zero was used to
define abstinence, whereas in the study of HJALMARSON
et al. [4], continuous abstinence from week 2 was used,
and in the study of SUTHERLAND et al. [3] there was an
initial 3 week period where slips were allowed. Suppor-
tive group treatment in the latter study consisted of six
sessions over a period of 1 month. The number of group
meetings in the study of HJALMARSON et al. [4] was eight
over 6 weeks, while it was six meetings over 6 weeks
in the present study, and none in the study of SCHNEIDER
et al. [5]. All authors used 10 ppm in the carbon mono-
xide analysis as the cut-off limits for smokers except
SCHNEIDER et al. [5], who used 9 ppm. All authors allow-
ed use of NNS for up to 12 months, except SCHNEIDER
et al. [5] who allowed NNS use until the 6 month fol-
low-up. In addition, the entrance criteria of the four
studies were not the same. The present study was the
only one that allowed use of psychotropic drugs. In all
four studies the use of nonprotocol nicotine was regar-
ded as equivalent to smoking. The study of SCHNEIDER
et al. [5] was the only one that required at least 15 cig-
arettes smoked·day-1 at entry and a minimum baseline
value of 20 ppm of CO. Compared to pretreatment val-
ues the substitution level was 30–40% after 4–6 weeks
and the number of doses·day-1 at that time was 13–15
in three of the studies. All the above-mentioned factors
may account for differences in observed abstinence
rates in the four studies (table 6).
The present study was designed to demonstrate dif-
ferences in the study groups (NNS and placebo) up to
at least 3 months. From the results (fig. 1, table 2), it
is concluded that the use of NNS is a useful aid in smok-
ing cessation. The effects of the NNS were even evi-
dent after only 1 day and persisted for at least 6 months.
After 1 day, 100% of the abstainers were using the spray,
at the 3 and 6 month follow-ups 65%, and at the 12
month follow-up 45%. The difference in efficacy was
not significant at the 1 yr follow-up nor after 2 yrs,
when all subjects had been off NNS for at least 1 yr.
The dose of NNS in the present study was self-
titrated within the recommend-
ed limits (<40 mg·day-1). The
design of the study did not pro-
vide for possibilities for dif-
ferent treatments. However the
results of the cotinine measure-
ments suggest that pretreat-
ment saliva cotinine levels (430
ng·mL-1 for the long-term NNS
users) might be used in indivi-
dual therapy to distinguish sub-
jects who will need many doses
of NNS (20–25 mg·day-1) from
those requiring few doses of
NNS. The mean level of sub-
stitution after 6 weeks was only
40%, which is high compared
to that obtained with other
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Table 5.  –  Change in adverse effects in abstinent subjects using nicotine nasal
spray (NNS) for full 6 weeks
Symptom None Mild Moderate Severe
1 day 6 weeks 1 day 6 weeks 1 day 6 weeks 1 day 6 weeks
Nasal irritation 13 24 46 48 36 7 5 0
Throat irritation 38 52 38 48 22 0 3 0
Coughing 61 86 18 14 21 0 0 0
Sneezing 28 44 36 48 33 8 3 0
Watery eyes 13 61 49 39 36 0 3 0
Runny nose 5 17 42 70 40 13 13 0
Palpitations 95 87 3 13 3 0 0 0
Nausea 95 91 5 4 0 4 0 0
Sweating 95 96 3 4 3 0 0 0
Headache 87 87 10 13 3 0 0 0
Calmness 44 44 31 35 26 22 0 0
Dizziness 80 96 18 4 3 0 0 0
Values indicate the percentage of subjects reporting symptoms, at the severity indicated,
after 1 day (n=40) and 6 weeks (n=29).
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Fig. 4.  –  Total score of all adverse effects among nonsmoking spray
users at each follow-up. After 1 day of use, adverse effects were
more common in the nicotine group than among those using the place-
bo, but the difference levelled out during the first 6 days after quit-
ting.     : nicotine nasal spray group;     : placebo group.
NRTs but low compared to the baseline smoking lev-
els.
The proper duration of NRT is not known. As SCHNEIDER
et al. [5] point out, 3–6 months of NRT may not be
enough to unlearn smoking behaviours after 20–40 yrs
of practice and reinforcement. Given that other factors
are controlled, smokers who are more dependent need
treatment for a longer time. Since one key factor in
stopping smoking is that the smoker must change his
or her self-image to that of a nonsmoker, behavioural
intervention and support is often vital. If behavioural
intervention is successfully applied, there should there-
fore be less need for long-term NRT. Judging from the
results of the 2 yr follow-up, we believe that for depen-
dent smokers an appropriate recommendation should in-
clude 6–18 months of lapse-free abstinence before NRT
is withdrawn.
In the present study, participants were encouraged to
use NNS often enough over a sufficient period of time
to be able to prevent a relapse. It should be noted that
the NNS was dispensed without cost to the participants.
Despite strong encouragement, it was not possible to
persuade most of the participants to increase their use
of NNS, either in quantity, or for a greater length of
time. This approach is therefore not a feasible way to
increase abstinence rates beyond those observed in this
study. Therefore, the present focus on the combined use
of different nicotine treatments and dosage patterns dur-
ing therapy is a worthwhile approach [13–15]. The
transdermal route is a fixed dose system with a low fre-
quency of adverse effects. Gum and/or spray are more
flexible drug delivery systems and ought to enable the
subject to adapt nicotine use in response to mood
changes during the day. Different delivery systems used
in combination should be superior to a single system in
bringing this about, particularly if the therapeutic ratio
is more favourable with combination therapies. Patients
on nicotine replacement therapy remain susceptible to
relapse and must change their self-image to become true
ex-smokers; otherwise, relapse is likely to occur upon
stopping nicotine replacement therapy.
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Table 6.  –  Continuous abstinence rates (%) in four controlled trials of nicotine nasal
spray (NNS)
Follow-up Present study HJALMARSSON et al. SCHNEIDER et al. SUTHERLAND et al.
time [4] [5] [3]
(n=157) (n=248) (n=255) (n=227)
NNS Placebo NNS Placebo NNS Placebo NNS Placebo
6 weeks 51 24 53 27 43 20 49 21†
3 months 39 19 41 20 34 13 41 17
6 months 29 18 35 15 25 10 32 12
12 months 25 17 27 15 18 8 26 10
24 months 19 14 - - - - - -
†: Abstinence rate at 2 months.
